Active Ingredient History
Cladribine is used for the treatment of hairy cell leukemia and multiple sclerosis (MS). As a purine analog, it is a synthetic anti-cancer agent that also suppresses the immune system. Chemically, it mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, which interferes with the cell's ability to process DNA. It can be distinguished from other chemotherapeutic agents affecting purine metabolism in that it is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNA synthesis and repair. Cladribine injection is a potent antineoplastic agent with potentially significant toxic side effects. In MS, the novel mechanism of action of cladribine is expected to reduce inflammation, autoimmune effects and autoreactive cell damage, thereby improving the integrity of the blood–brain barrier. Thus, the effects of cladribine may target some of the key events that are central to the pathophysiology of MS. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Leukemia, Hairy Cell (approved 1995)
Bone Marrow Cells (Phase 2)
Brain Neoplasms (Phase 1)
Burkitt Lymphoma (Phase 2)
Cholangitis, Sclerosing (Phase 2)
GATA2 Deficiency (Phase 2)
Geriatrics (Phase 2)
Graft vs Host Disease (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 3)
Histiocytosis, Langerhans-Cell (Phase 2/Phase 3)
Hodgkin Disease (Phase 2)
Intestinal Neoplasms (Phase 1)
Leukemia (Phase 3)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 2/Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 2/Phase 3)
Leukemia, Myeloid (Phase 2/Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 3)
Lymphoma, T-Cell, Peripheral (Phase 3)
Mastocytosis, Systemic (Phase 2/Phase 3)
Multiple Myeloma (Phase 1)
Multiple Sclerosis (Phase 4)
Multiple Sclerosis, Chronic Progressive (Phase 2/Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Precancerous Conditions (Phase 1)
Recurrence (Phase 1)
Sarcoma (Phase 1)
Sarcoma, Myeloid (Phase 2)
Squamous Intraepithelial Lesions (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
